Oncology

From the first approved CAR T therapy for multiple myeloma, to the recently-approved ciltacabtagene autoleucel, significant steps have been taken.

The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for previously treated HER2-positive breast cancer and gastric or gastroesophageal junction adenocarcinoma.

Experts discuss tools and trainings that health care institutions have established during the pandemic to support hematology-oncology pharmacists who are struggling with wellness and mental health challenges.

Screening participation increased over time, but the increase was smallest among individuals aged 50 to 54.

An intelligence-based system could help improve the timeliness of referrals to palliative care and hospice services in a community oncology environment.

Rucaparib (Rubraca) is a poly (ADP-ribose) polymerase (PARP) inhibitor used for ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and castration-resistant prostate cancer.

James McCloskey, MD, analyzes result data from the QUAZAR AML-001 trial that focused on oral azacitidine.

Cole McCoy, PharmD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP explain the additional agents being studied as maintenance therapy options.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses how pharmacists can support patients with cancer who have a much higher risk of heart disease.

By using technology solutions, pharmacists can be further integrated into the care team.

Christine Walko, PharmD, BCOP, FCCP, discusses some new developments for PARP inhibitors in cancer care for patients with homologous recombination deficiency.

Christopher Fine, MD, FACC, a cardiologist at National Jewish Health, discusses the relationship between heart disease and cancer and the importance of the field of cardio-oncology when treating patients with cancer.

Findings suggest that the HER2 L755S mutation plays a role in the aggressiveness of lobular breast cancer observed in the clinic.

Autologous stem cell transplantation was underutilized in community settings for mantle cell lymphoma.

Although treating mental health symptoms is essential, finding the time and energy for more appointments can be challenging for patients with cancer.

Dr James McCloskey discusses patient selection for AML maintenance therapy, as well as novel agents that are being evaluated in this setting.

Thrombocytopenia was the most common adverse effect, which was managed through dose reduction.

The panel describes the various roles and responsibilities for each member of an AML management care team.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss research conducted looking to assess the hematology-oncology pharmacist “great migration” from the field.

Ken Thorpe, PhD, professor of public health at Emory University and chairman of Partnership to Fight Chronic Disease, discusses legislation that the US House of Representatives recently passed to put greater restrictions on the FDA’s accelerated approval pathway.

Clinical trial results show durable responses with mosunetuzumab in advanced follicular lymphoma.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss the underlying causes of the hematology-oncology pharmacist great migration from the field.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses methods of accomplishing greater workforce diversity in the field of oncology pharmacy.

Bhavesh Shah, RPh, BCOP, steering committee co-chair of the 2022 ATOPP Summit, discusses the impact of the annual ATOPP summit on the oncology pharmacy field.

Sonidegib is a biphenyl carboxamide that blocks the signaling in the hedgehog pathway.

This webcast discusses opportunities for pharmacists to address the cost of cancer care and enable improved access and outcomes for patients. During the webcast, a panel of experts discusses how pharmacists can help minimize costs associated with cancer therapy, including treatment and clinical practice considerations, as well as more direct financial support that can help ensure access to effective therapies for patients. Additional Resource Guide can be found here: https://www.pharmacytimes.com/view/managing-cancer-cost-resource-guide.

Nearly 63% of newly diagnosed patients have advanced colorectal cancer, which requires more aggressive treatment and reduces the associated 5-year survival rate.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses the importance of putting precision medicine programs into oncology practices with pharmacists leading the way.

Pharmacy Times will be covering the 2022 ATOPP Summit live in San Diego, CA.

Amy Woodard, PharmD, BCOP, the steering committee co-chair of the 2022 ATOPP Summit, highlights key topics and discussions at the in-person summit in July in San Diego, CA.